Martha Mayo

4.0k total citations · 3 hit papers
45 papers, 2.7k citations indexed

About

Martha Mayo is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Physiology. According to data from OpenAlex, Martha Mayo has authored 45 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 12 papers in Cardiology and Cardiovascular Medicine and 7 papers in Physiology. Recurrent topics in Martha Mayo's work include Potassium and Related Disorders (23 papers), Heart Failure Treatment and Management (12 papers) and Electrolyte and hormonal disorders (8 papers). Martha Mayo is often cited by papers focused on Potassium and Related Disorders (23 papers), Heart Failure Treatment and Management (12 papers) and Electrolyte and hormonal disorders (8 papers). Martha Mayo collaborates with scholars based in United States, United Kingdom and France. Martha Mayo's co-authors include Dahlia Garza, Matthew R. Weir, George L. Bakris, Lance Berman, David A. Bushinsky, Yuri Stasiv, Thomas Saul, Gerald D. Silverberg, Dawn McGuire and Bertram Pitt and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Martha Mayo

45 papers receiving 2.6k citations

Hit Papers

Patiromer in Patients with Kidney Disease and Hyperkalemi... 2014 2026 2018 2022 2014 2015 2019 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
    2014 453 citations Matthew R. Weir, George L. Bakris et al. New England Journal of Medicine profile →
  2. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease
    2015 312 citations George L. Bakris, Bertram Pitt et al. JAMA profile →
  3. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
    2019 215 citations Rajiv Agarwal, Patrick Rossignol et al. The Lancet profile →

Peers

Martha Mayo
Eliana Lucchinetti Switzerland
Shosuke Takahashi Japan
Torsten Loop Germany
Nina C. Weber Netherlands
Tapio Viljanen Finland
Paul A. Murray United States
Bobby D. Nossaman United States
Robert Ginsburg United States
Hirotsugu Okamoto Japan
Toshiaki Ebina Japan
Eliana Lucchinetti Switzerland
Martha Mayo
Citations per year, relative to Martha Mayo Martha Mayo (= 1×) peers Eliana Lucchinetti

Countries citing papers authored by Martha Mayo

Since Specialization
Citations

This map shows the geographic impact of Martha Mayo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martha Mayo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martha Mayo more than expected).

Fields of papers citing papers by Martha Mayo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martha Mayo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martha Mayo. The network helps show where Martha Mayo may publish in the future.

Co-authorship network of co-authors of Martha Mayo

This figure shows the co-authorship network connecting the top 25 collaborators of Martha Mayo. A scholar is included among the top collaborators of Martha Mayo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martha Mayo. Martha Mayo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rossignol, Patrick, Bryan Williams, Martha Mayo, et al.. (2020). Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( AMBER ): Results in the Pre-Specified Subgroup with Heart Failure. European Journal of Heart Failure. 22(8). 1462–1471. 25 indexed citations
2.
Agarwal, Rajiv, Patrick Rossignol, Alain Romero, et al.. (2019). Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. 394(10208). 1540–1550. 215 indexed citations breakdown →
3.
Agarwal, Rajiv, Patrick Rossignol, Dahlia Garza, et al.. (2018). Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study. American Journal of Nephrology. 48(3). 172–180. 17 indexed citations
4.
5.
Weir, Matthew R., David A. Bushinsky, Wade W. Benton, et al.. (2017). Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. The American Journal of Medicine. 131(5). 555–564.e3. 33 indexed citations
6.
Bushinsky, David A., Alain Romero, Charles Du Mond, Martha Mayo, & Markus Ketteler. (2017). TO028EFFECT OF PATIROMER ON SERUM POTASSIUM IN HYPERKALEMIC PATIENTS WITH SEVERE CKD ON RAAS INHIBITORS: RESULTS FROM OPAL-HK AND AMETHYST-DN. Nephrology Dialysis Transplantation. 32(suppl_3). iii89–iii91. 4 indexed citations
7.
Weir, Matthew R., George L. Bakris, Coleman Gross, et al.. (2016). Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney International. 90(3). 696–704. 50 indexed citations
8.
Epstein, Murray, Martha Mayo, Dahlia Garza, et al.. (2015). Abstract 14271: Patiromer Controls Hyperkalemia in Resistant Hypertensive Patients on RAASi, With Diabetic Kidney Disease. Circulation. 132(suppl_3). 6 indexed citations
9.
Pitt, Bertram, George L. Bakris, David A. Bushinsky, et al.. (2015). Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas Inhibitors. European Journal of Heart Failure. 17(10). 1057–1065. 117 indexed citations
10.
Bakris, George L., Bertram Pitt, Matthew R. Weir, et al.. (2015). Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease. JAMA. 314(2). 151–151. 312 indexed citations breakdown →
11.
Weir, Matthew R., George L. Bakris, David A. Bushinsky, et al.. (2014). Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. New England Journal of Medicine. 372(3). 211–221. 453 indexed citations breakdown →
12.
Fishbane, Steven, Brigitte Schiller, Francesco Locatelli, et al.. (2013). Peginesatide in Patients with Anemia Undergoing Hemodialysis. New England Journal of Medicine. 368(4). 307–319. 69 indexed citations
13.
Macdougall, Iain C., Robert Provenzano, Amit Sharma, et al.. (2013). Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis. New England Journal of Medicine. 368(4). 320–332. 78 indexed citations
14.
Macdougall, Iain C., Andrzej Więcek, Beatriz Tucker, et al.. (2011). Dose-finding Study of Peginesatide for Anemia Correction in Chronic Kidney Disease Patients. Clinical Journal of the American Society of Nephrology. 6(11). 2579–2586. 18 indexed citations
15.
Silverberg, Gerald D., et al.. (2008). Continuous CSF drainage in AD. Neurology. 71(3). 202–209. 61 indexed citations
16.
Wallace, Mark S., Steven G. Charapata, Robert B. Fisher, et al.. (2006). Intrathecal Ziconotide in the Treatment of Chronic Nonmalignant Pain: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Neuromodulation Technology at the Neural Interface. 9(2). 75–86. 130 indexed citations
17.
Staats, Peter S., Thomas Yearwood, Steven G. Charapata, et al.. (2004). Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients With Cancer or AIDS. JAMA. 291(1). 63–63. 404 indexed citations
18.
Silverberg, Gerald D., et al.. (2004). Novel ventriculoperitoneal shunt in Alzheimer´s disease cerebrospinal fluid biomarkers. Expert Review of Neurotherapeutics. 4(1). 97–107. 12 indexed citations
19.
Silverberg, Gerald D., Martha Mayo, Thomas Saul, Edward Rubenstein, & Dawn McGuire. (2003). Alzheimer's disease, normal‐pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. The Lancet Neurology. 2(8). 506–511. 326 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eliana Lucchinetti Breakdown of academic impact, for papers by Shosuke Takahashi Breakdown of academic impact, for papers by Torsten Loop Breakdown of academic impact, for papers by Nina C. Weber Breakdown of academic impact, for papers by Tapio Viljanen Breakdown of academic impact, for papers by Paul A. Murray Breakdown of academic impact, for papers by Bobby D. Nossaman Breakdown of academic impact, for papers by Robert Ginsburg Breakdown of academic impact, for papers by Hirotsugu Okamoto Breakdown of academic impact, for papers by Toshiaki Ebina
Rankless by CCL
2026